Upgrade to SI Premium - Free Trial

Neurocrine Bio. (NBIX) PT Lowered to $214 at UBS, Buy Rating Maintained

September 29, 2026 9:12 AM
UBS analyst Ashwani Verma lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $214.00 (from $231.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change